Kelzyn (Dienogest, Ethinylestradiol | Lactose)

The formulation contains dienogest, a progestogen, and ethinylestradiol, an estrogen. Together they inhibit the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), preventing ovulation. Additionally, they thicken cervical mucus and alter the endometrium, reducing the chance of fertilisation and implantation.

The dosing regimen for Kelzyn is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily for a defined cycle, but the exact schedule, tablet strength and duration should follow the prescriber's instructions and the product label.

Kelzyn is classified as pregnancy category X, meaning it must not be used during pregnancy because it can cause harm to the fetus. Safety during breastfeeding has not been established; women should consult their healthcare provider before using any hormonal contraceptive while nursing.

To order Kelzyn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Kelzyn contains the specific progestogen dienogest combined with ethinylestradiol, offering a distinct hormonal profile that may provide better cycle control and lower androgenic side effects compared with some older formulations. Efficacy in preventing pregnancy is comparable to other approved combined pills, while the side‑effect profile may differ slightly.

Kelzyn tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Kelzyn is taken orally, usually once daily at the same time each day, following the regimen outlined by the prescriber (e.g., 21 active tablets followed by a placebo week). Swallow the tablet whole with water; do not split, crush, or chew the tablet.

Serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rare but severe reactions can involve severe allergic responses, liver dysfunction, and vision changes. Patients should seek immediate medical attention if they experience symptoms like chest pain, shortness of breath, severe headache, or leg swelling.

Kelzyn should not be used by women who are pregnant, have a known hypersensitivity to any component, have a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, or are smokers over the age of 35. It is also contraindicated in individuals with certain hormone‑sensitive cancers.